Table 1.
Characteristics of all study participants at screening and by treatment assignment at completion of placebo run-in
| Screening visit | Baseline visit |
||
|---|---|---|---|
| Characteristic | All subjects (n = 53) | Placebo (n = 27) | Losartan (n = 26) |
| Age (years) | 52.5 (9.5) | 53.8 (8.3) | 51.1 (10.5) |
| Sex (female) (n) | 26 (49.1 %) | 12 (44.4 %) | 14 (53.8 %) |
| Race | |||
| White (n) | 40 (75.4 %) | 24 (88.9 %) | 16 (61.5 %) |
| Black (n) | 10 (18.9 %) | 1 (3.7 %) | 9 (34.6 %) |
| Other (n) | 3 (5.7 %) | 2 (7.4 %) | 1 (3.8 %) |
| Taking antihypertensive therapy (n) | 1 (1.9 %) | 0 | 1 (3.8 %) |
| Weight (kg) | 101.2 (13.5) | 101.6 (14.1) | 101.0 (13.7) |
| BMI (kg/m2) | 34.7 (3.8) | 34.7 (3.8) | 34.8 (3.8) |
| Waist circumference (cm)* | 111.2 (9.9) | n/a | n/a |
| SBP (mmHg) | 136.0 (10.8) | 135.0 (9.6) | 136.3 (10.9) |
| DBP (mmHg) | 87.2 (6.4) | 86.6 (5.3) | 88.7 (5.3) |
| Heart rate (beats/min) | 71.5 (10.6) | 74.8 (12.2) | 72.4 (9.2) |
| Potassium (mmol/l) | 4.3 (0.3) | 4.0 (3.3, 4.7) | 4.1 (3.6, 4.9) |
| Glucose (mmol/l) | 104.8 (8.6) | 97.5 (1.7) | 97.5 (1.7) |
| Insulin (μ-units/ml) | 14.3 (8.0) | 10.2 (0.9) | 11.7 (1.2) |
| HOMA-IR | 3.8 (2.3) | 2.5 (0.2) | 2.9 (0.3) |
| Triacyglycerols (mmol/l) | n/a | 136.5 (56.0, 309.0) | 113.0 (51.0, 235.0) |
| HDL-cholesterol (mmol/l) | n/a | 44.0 (22.0, 77.0) | 43.0 (31.0, 83.0) |
| Creatinine (mg/dl) | 1.0 (0.2) | 0.93 (0.03) | 0.88 (0.04) |
| Urine albumin/creatinine ratio (mg/mmol) | n/a | 1.22 (0.35) | 1.02 (0.18) |
*
Measured at the screening visit only.
Continuous variables as means (S.E.M.) or medians (range). HDL, high-density lipoprotein; n/a, not available.